What's Happening?
Amgen's bispecific T-cell engager (BiTE), Imdelltra, has received approval from the EMA's human medicines committee as a second-line treatment for extensive-stage small cell lung cancer (ES-SCLC). Imdelltra targets the DLL3 protein on cancer cells and
the CD3 antigen on T cells, activating the immune system to attack tumors. The approval follows positive results from the phase 3 DeLLphi-304 study, which showed a 40% reduction in the risk of death and extended median overall survival compared to standard chemotherapy. This marks a significant advancement in lung cancer treatment options.
Why It's Important?
The approval of Imdelltra in the EU represents a major milestone in cancer treatment, offering a new therapeutic option for patients with ES-SCLC. This development could lead to improved survival rates and quality of life for patients, while also driving innovation in cancer immunotherapy. The success of Imdelltra may encourage further research and investment in bispecific antibodies, potentially leading to breakthroughs in other cancer types. The approval also highlights the importance of international collaboration in advancing medical treatments.
